<div id="readability-page-1"><p>Bayesian Capital Management LP acquired a new position in shares of  Insulet Corporation (NASDAQ:PODD - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor  acquired 12,400 shares of the medical instruments supplier's stock, valued at approximately $3,896,000.</p><ul><li>3 Medical Technology Stocks Outperforming in 2025</li></ul><p>Several other institutional investors have also recently bought and sold shares of PODD. Marshall Financial Group LLC bought a new position in shares of  Insulet during the 2nd quarter worth about $943,000.  Inspire Investing LLC grew its position in  Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after buying an additional 3,088 shares in the last quarter.  Illinois Municipal Retirement Fund increased its stake in  Insulet by 41.3% during the second quarter. Illinois Municipal Retirement Fund now owns 12,030 shares of the medical instruments supplier's stock valued at $3,780,000 after acquiring an additional 3,514 shares during the period.  Gradient Investments LLC acquired a new position in  Insulet in the 2nd quarter valued at approximately $17,429,000.  Finally, Goldman Sachs Group Inc. lifted its position in shares of  Insulet by 1.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock worth $152,130,000 after acquiring an additional 10,628 shares during the period. </p><h2>Insulet Price Performance</h2><p>PODD opened at $294.17 on Friday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The stock has a market capitalization of $20.69 billion, a P/E ratio of 85.27, a price-to-earnings-growth ratio of 2.08 and a beta of 1.37. The company's 50 day simple moving average is $319.15 and its 200-day simple moving average is $315.14. Insulet Corporation has a one year low of $230.05 and a one year high of $354.88. </p><ul><li>Insulet Surges on Q1 Beat, Emerges as a Top S&amp;P 500 Performer</li></ul><p>Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.11. The firm had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The business's revenue for the quarter was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.08 EPS.  Sell-side analysts anticipate that  Insulet Corporation will post 3.92 earnings per share for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>PODD has been the topic of a number of research reports. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of Insulet in a research report on Wednesday, October 8th. Zacks Research upgraded shares of Insulet from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, October 14th. Stifel Nicolaus initiated coverage on shares of Insulet in a research note on Tuesday, October 21st. They issued a &#34;buy&#34; rating and a $370.00 price objective for the company. BTIG Research raised their price objective on shares of Insulet from $370.00 to $380.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, November 21st. Finally, Leerink Partners upped their target price on shares of Insulet from $385.00 to $386.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, November 21st. One research analyst  has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $379.65.</p><ul><li>Are These 5 Undervalued Stocks Ready to Break Out?</li></ul><p><b>Read Our Latest Stock Analysis on PODD</b></p><h2>Insulet Profile</h2> (Free Report)<p>Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Insulet</li><li>When to Sell a Stock for Profit or Loss</li><li>3 Recently Downgraded Stocks to Avoid in 2026</li><li>How to Short a Stock in 5 Easy Steps </li><li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li><li>The Role Economic Reports Play in a Successful Investment Strategy</li><li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li></ul><p><strong>Want to see what other hedge funds are holding PODD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Insulet Right Now?</h2><p>Before you consider Insulet, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p><p>While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PODD

<p>Bayesian Capital Management LP acquired 12,400 shares of Insulet Corporation, valued at approximately $3.90 million, during the second quarter. This investment was disclosed in a recent SEC filing. Other institutional investors have also increased their positions in Insulet, indicating strong interest in the medical instruments supplier. Insulet's stock performance and financial metrics, including a market cap of $20.69 billion and a P/E ratio of 85.27, are highlighted. Analysts have given the stock a "Moderate Buy" rating with a target price of $379.65.</p>

Bayesian Capital Management LP Invests $3.90 Million in Insulet Corporation $PODD